SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-24-016346
Filing Date
2024-09-11
Accepted
2024-09-11 16:30:38
Documents
57
Period of Report
2024-07-31

Document Format Files

Seq Description Document Type Size
1 z9624010q.htm   iXBRL 10-Q 648328
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7909
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7618
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 5007
  Complete submission text file 0001214659-24-016346.txt   3670065

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20240731.xsd EX-101.SCH 37208
6 XBRL CALCULATION FILE alzm-20240731_cal.xml EX-101.CAL 30401
7 XBRL DEFINITION FILE alzm-20240731_def.xml EX-101.DEF 116678
8 XBRL LABEL FILE alzm-20240731_lab.xml EX-101.LAB 256962
9 XBRL PRESENTATION FILE alzm-20240731_pre.xml EX-101.PRE 207906
59 EXTRACTED XBRL INSTANCE DOCUMENT z9624010q_htm.xml XML 480398
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 241292973
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)